Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Kosan, Roche deal

KOSN and ROG will end a 2002 deal to develop and market epothilone

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE